Huperzia Seratta Extract 1% Huperzine A

★ Huperzine-A is a compound extracted from the herbs of the Huperziceae family, Huperzia serrata.

★ Huperzine-A is known as an acetylcholinesterase inhibitor, it stops an enzyme from breaking down acetylcholine which results in increases in acetylcholine.

★ Huperzine-A appears to be a relatively safe compound from animal studies of toxicity and studies in humans showing no side-effects at dosages routinely supplemented with.

The Brief Info

Product Name Huperzia Serrata Extract
Specification Huperzine A not less than 1.0%
Description Yellow brown powder
Sterilization Method Dry heat. Non-irradiated.
BSE/TSE Not of animal origin.BSE TSE free. 
Allergen Known allergen free. 
Gluten Gluten free. 
Storage Store in a cool dry place,away from direct sunlight

The Detail

1. Neuroprotectant

Oxidative damage is at the center of most age-related illnesses, it is believed to play a major role in the development of neurological disorders.‍ Among the most important benefits of Huperzine A is its ability to protect the brain from oxidative damage. Huperzine A is a potent antioxidant that has been shown to positively affect oxidative balance‍ and is considered a safe, effective, and well-tolerated supplements for Alzheimer’s.


2. Memory Enhancer

Huperzine A can improve memory by improving brain levels of acetylcholine, an important neurotransmitter crucial to all aspects of cognition.


3. Relieves Symptoms of Depression

A review of three clinical trials suggests that huperzine A supplementation may be effective in alleviating the cognitive impairment symptoms of major depressive disorders.



1) Beatty S, Koh H, Phil M, Henson D, Boulton M.The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000

2) JT Little, S Walsh, P Aisen An update on huperzine A as a treatment for Alzheimer’s disease Expert Opinion Journal 2008

3) Zheng W, Xiang YQ, etal. Huperzine A for treatment of cognitive impairment in major depressive disorder: a systematic review of randomized controlled trials. Shanghai Arch Psychiatry. 2016